99 related articles for article (PubMed ID: 27070757)
21. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
[TBL] [Abstract][Full Text] [Related]
22. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
23. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
Lopotová T; Záčková M; Klamová H; Moravcová J
Leuk Res; 2011 Jul; 35(7):974-7. PubMed ID: 21511335
[TBL] [Abstract][Full Text] [Related]
25. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
[TBL] [Abstract][Full Text] [Related]
26. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
27. Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA.
Li MJ; McMahon R; Snyder DS; Yee JK; Rossi JJ
Oligonucleotides; 2003; 13(5):401-9. PubMed ID: 15000831
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
29. miR-140-5p induces cell apoptosis and decreases Warburg effect in chronic myeloid leukemia by targeting SIX1.
Nie ZY; Liu XJ; Zhan Y; Liu MH; Zhang XY; Li ZY; Lu YQ; Luo JM; Yang L
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30962263
[TBL] [Abstract][Full Text] [Related]
30. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
[TBL] [Abstract][Full Text] [Related]
31. RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
Futami M; Hatano T; Soda Y; Kobayashi S; Miyagishi M; Tojo A
Leukemia; 2008 Jun; 22(6):1131-8. PubMed ID: 18368071
[TBL] [Abstract][Full Text] [Related]
32. MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.
Liu YX; Wang L; Liu WJ; Zhang HT; Xue JH; Zhang ZW; Gao CJ
J Hematol Oncol; 2016 Aug; 9(1):69. PubMed ID: 27516205
[TBL] [Abstract][Full Text] [Related]
33. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
34. Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.
Zhu X; Zhao H; Lin Z; Zhang G
Cancer Gene Ther; 2015 Dec; 22(12):573-80. PubMed ID: 26494558
[TBL] [Abstract][Full Text] [Related]
35. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Fallah P; Amirizadeh N; Poopak B; Toogeh G; Arefian E; Kohram F; Hosseini Rad SM; Kohram M; Teimori Naghadeh H; Soleimani M
Int J Lab Hematol; 2015 Aug; 37(4):560-8. PubMed ID: 25833191
[TBL] [Abstract][Full Text] [Related]
36. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein.
Li Y; Wang H; Tao K; Xiao Q; Huang Z; Zhong L; Cao W; Wen J; Feng W
Exp Cell Res; 2013 May; 319(8):1094-101. PubMed ID: 23428668
[TBL] [Abstract][Full Text] [Related]
37. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
38. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
39. Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia.
Hussein K; Büsche G; Muth M; Göhring G; Kreipe H; Bock O
Ann Hematol; 2011 Mar; 90(3):307-13. PubMed ID: 20842500
[TBL] [Abstract][Full Text] [Related]
40. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
